Clinical Considerations for Biosimilar Antibodies

Biosimilars, which are near copies of branded biologics, may cost far more to bring to market than standard generics, but their growth rate is now reaching 20% a year. To ensure safety and success, biosimilars require strong clinical development and pharmacovigilance plans.

Where do biosimilar monoclonal antibodies (mAbs) fit in? (PDF, 596kb)